Finds that adding mycophenolate mofetil to rituximab does not enhance treatment outcomes in pemphigus, suggesting caution in its use.
Rituximab is an effective treatment for pemphigus but it is not known whether continuation of mycophenolate mofetil (MMF) after treatment improves clinical outcomes. This study demonstrates that continuation of MMF with prednisolone is not associated with improved or prolonged treatment responses compared to prednisolone alone. Adjuvant treatment with MMF was, however, associated with a CD8 T cell lymphopaenia suggestive of an increased risk of infection.
No takes yet. Share an insight, caveat, or question.
Naidu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: